Genes enriched in Arm B as compared to Arm A include CXCL13, an important chemokine in tertiary lymphoid structure development37 that was shown to be a marker of response to anti-PD1 therapy when expressed by tumor infiltrating CD8+ T cells in NSCLC,32 as well as the activation markers TNFRSF9 (CD137/4-1BB) and KLRB1 (CD161). This evidence concerns the gene TNFRSF9 and non-small cell lung carcinoma.